Core Viewpoint - YKYY018 aerosol inhalation agent developed by Yuyuan Pharmaceutical has received FDA approval for clinical trials, marking a significant step in addressing the unmet medical need for RSV infection treatment globally, as no such drug has been approved for market yet [1] Company Summary - Yuyuan Pharmaceutical's subsidiary, Beijing Yuyuan Kexin Pharmaceutical Technology Co., Ltd., has obtained FDA approval for YKYY018 to be used in clinical trials for the prevention and treatment of RSV infection [1] - YKYY018 is an internationally original membrane fusion inhibitor drug developed through a comprehensive AI platform [1] Industry Summary - There is a significant and urgent unmet medical need in the clinical treatment field for RSV infections, as there are currently no approved drugs available globally for this indication [1]